Proactive analyst Emma Ulker talks to Proactive London about Open Orphan ().
She says ORPH has firmly established its core pharma services offering, underpinned
by the world-leading quarantine facilities, unique challenge study models and its established clinical trial services.
ORPH is focusing on converting an extensive and substantial amount of non-Covid-19 related services worth over £100mln. This is in addition to substantial contracts already
signed with the UK Government for COVID-19 vaccine challenge studies.
Click here to read Proactive analyst Emma Ulker's latest research note on 'Open Orphan: Unlocking the value of non-core assets'
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...
FOR OUR FULL DISCLAIMER CLICK HERE